---
title: Test fexofenadine for motor improvement
nct_id: NCT06785298
phase: PHASE2, PHASE3
status: RECRUITING
sponsor: Tanta University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06785298"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06785298"
last_fetched: "2026-05-10T14:04:16.916Z"
source: "Parkinson's Pathways (curated)"
---
# Test fexofenadine for motor improvement

**Goal (in five words):** Test fexofenadine for motor improvement

**Official Title:** Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment

**Trial ID:** [NCT06785298](https://clinicaltrials.gov/study/NCT06785298)

## Key Facts

- **Phase:** PHASE2, PHASE3
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Tanta University
- **Target Enrollment:** 46 participants
- **Start Date:** 2024-12-10
- **Completion Date:** 2026-12-10
- **Conditions:** Parkinson Disease
- **Interventions:** Levodopa/carbidopa, Fexofenadine
- **Intervention Types:** DRUG

## Summary For Families

The goal is to see whether adding fexofenadine to standard levodopa/carbidopa can safely improve Parkinson's symptoms or the overall response to dopamine replacement, while checking for side effects. Fexofenadine is an oral, non-sedating H1 antihistamine that blocks peripheral histamine receptors and has minimal brain penetration, so the trial is testing whether blocking histamine signaling outside the brain changes motor or non-motor symptoms, affects levodopa-related effects, or reduces inflammation without causing sedation or drug interactions. They're enrolling men and women age 50 to 70 with Parkinson's at Hoehn and Yahr stages 1 to 4 who are already on dopamine replacement, excluding people with atypical parkinsonism, significant liver, kidney, or heart problems, pregnancy or breastfeeding, substance abuse, or known allergy to the medications.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 70 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:• Age ≥ 50 years. Both male and female will be included. Patients with Parkinson's disease on dopamine replacement therapy. Modified Hoehn and Yahr stage, MHY 1-4

Exclusion Criteria:• Atypical parkinsonism or drug-induced parkinsonism Breast feeding Pregnant women and women with planned pregnancy. Patients with significant liver and kidney function abnormalities. History/presence of acute heart disease Alcohol and / or drug abusers. Patients with known allergy to the study medications Other medical conditions that can interfere with results or endanger the participant.
```

## Locations (1)

- Tanta University, Tanta, Egypt _(30.7885, 31.0019)_
  - Ihab Elsayed Hassan, MSC — (CONTACT) — 01067831661 — ihassan@horus.edu.eg

## Central Contacts

- Ihab Elsayed Hassan, Doctor — (CONTACT) — 0201067831661 — ihassan@horus.edu.eg

---

*Canonical: https://parkinsonspathways.com/trial/NCT06785298*  
*HTML version: https://parkinsonspathways.com/trial/NCT06785298*  
*Source data: https://clinicaltrials.gov/study/NCT06785298*